US · LFMD · MEDICAL - PHARMACEUTICALS
LifeMD, Inc. (LFMD) intrinsic value and stock valuation
$1.45as of 2026-11-21 · Mkt cap 172.17M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
LifeMD, Inc. DCF and intrinsic value
InvestorsCraft values LFMD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LFMD’s statements →
LifeMD, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Cerus Corporation (CERS) $1.85
- Sight Sciences, Inc. (SGHT) $10.18
- 908 Devices Inc. (MASS) $8.67
- Alpha Teknova, Inc. (TKNO) $7.63
- Sanara MedTech Inc. (SMTI) $32.55
- Senseonics Holdings, Inc. (SENS) $8.02
- High Tide Inc. (HITI) $2.23
- CVRx, Inc. (CVRX) $0.50
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $194.1M | $212.5M | $152.6M | $119M | $92.9M |
| Operating income | -$-7.67M | -$-16.14M | -$-14.49M | -$-43.45M | -$-54.3M |
| Net income | -$-7.11M | -$-18.88M | -$-20.6M | -$-45.54M | -$-60.9M |
| EPSd | -$-157.54K | -$-458.25K | -$-607.49K | -$-1.47M | -$-2.25M |
| Operating cash flow | $8.28M | $17.5M | $8.82M | -$-22.94M | -$-33.09M |
| Capital expenditure | -$-9.52M | -$-11.54M | -$-8.73M | -$-12.89M | -$-3.4M |
| Free cash flow | -$-1.24M | $5.98M | $90K | -$-35.83M | -$-36.49M |
| Total assets | $70.4M | $72.5M | $58.5M | $25.7M | $49.9M |
| Total debt | $6.32M | $25.1M | $18.9M | $4.13M | $1.85M |
| Net debt | -$-30.46M | -$-9.9M | -$-14.21M | $170K | -$-39.48M |
| Total equity | $23.2M | -$-4.05M | $5.57M | -$-7.31M | $25.8M |
| Cash and short-term investments | $36.8M | $35M | $33.2M | $3.96M | $41.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $194.1M | $212.5M | $152.6M | $119M | $92.9M |
| Cost of revenue | $39.3M | $24.1M | $18.9M | $18.7M | $18M |
| Gross profit | $154.8M | $188.4M | $133.7M | $100.4M | $74.9M |
| Research and development expenses | $7.35M | $9.51M | $6.06M | $2.97M | $950K |
| Selling, general and administrative expenses | $144M | $175.7M | $128.2M | $125.3M | $122.1M |
| Other expenses | $11.1M | $19.3M | $13.9M | $15.5M | $6.16M |
| Operating expenses | $162.4M | $204.5M | $148.1M | $143.8M | $129.2M |
| Cost and expenses | $201.7M | $228.6M | $167M | $162.5M | $147.2M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $1.36M | $2.18M | $2.6M | $1.28M | $3.02M |
| Depreciation and amortization | $7.31M | $9.49M | $6.6M | $1.09M | $360K |
| Ebitda | -$-1.52M | -$-6.65M | -$-8.21M | -$-38.6M | -$-57.94M |
| Operating income | -$-7.67M | -$-16.14M | -$-14.49M | -$-43.45M | -$-54.3M |
| Total other income/expenses, net | -$-2.52M | -$-2.18M | -$-2.92M | -$-1.21M | -$-7.02M |
| Income before tax | -$-10.19M | -$-18.33M | -$-17.41M | -$-44.66M | -$-61.32M |
| Income tax expense | $50K | $400K | $430K | $360K | $10K |
| Net income | -$-7.11M | -$-18.88M | -$-20.6M | -$-45.54M | -$-60.9M |
| Weighted average shares outstanding | $45.1M | $41.2M | $33.9M | $31M | $27M |
| Weighted average diluted shares outstanding | $45.1M | $41.2M | $33.9M | $31M | $27M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $36.8M | $35M | $33.2M | $3.96M | $41.3M |
| Net receivables | $9.31M | $8.22M | $5.28M | $2.83M | $980K |
| Inventory | $2.77M | $2.8M | $2.76M | $3.7M | $1.62M |
| Total current assets | $51.8M | $48.7M | $42.6M | $11.3M | $44.9M |
| Property, plant and equipment, net | $5.27M | $7.88M | $1.07M | $1.68M | $1.99M |
| Goodwill and intangible assets | $260K | $15.9M | $14.8M | $12.7M | $3.02M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $18.6M | $23.7M | $15.9M | $14.4M | $5M |
| Total assets | $70.4M | $72.5M | $58.5M | $25.7M | $49.9M |
| Accounts payable | $14.2M | $16M | $11.1M | $10.1M | $9.06M |
| Short-term debt | $640K | $8.95M | $930K | $3.55M | $670K |
| Deferred revenue | $10.8M | $14.5M | $8.83M | $5.55M | $1.5M |
| Total current liabilities | $41.6M | $60.3M | $34.8M | $31.4M | $22.8M |
| Long-term debt | $5.68M | $16.2M | $18M | $570K | $1.18M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $5.68M | $16.3M | $18.1M | $1.6M | $1.28M |
| Capital lease obligations | $6.32M | $6.77M | $680K | $1.33M | $1.79M |
| Total liabilities | $47.3M | $76.5M | $52.9M | $33M | $24.1M |
| Common stock | $470K | $420K | $380K | $320K | $310K |
| Retained earnings | -$-228.6M | -$-236.25M | -$-214.27M | -$-190.56M | -$-141.92M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $23.2M | -$-4.05M | $5.57M | -$-7.31M | $25.8M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $6.32M | $25.1M | $18.9M | $4.13M | $1.85M |
| Net debt | -$-30.46M | -$-9.9M | -$-14.21M | $170K | -$-39.48M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $15.6M | -$-18.73M | -$-20.6M | -$-45.02M | -$-61.32M |
| Depreciation and amortization | $330K | $9.49M | $6.6M | $3.77M | $870K |
| Stock-based compensation | $10.5M | $12.2M | $12.5M | $13.7M | $12.1M |
| Change in working capital | -$-7.85M | $12.7M | $4.91M | -$-1.55M | $9.13M |
| Accounts receivable | $1.15M | -$-2.94M | -$-2.44M | -$-2.19M | $20K |
| Inventory | $300K | $680K | $760K | -$-2.18M | -$-410K |
| Accounts payable | $3.24M | $4.92M | $980K | $1.25M | -$-890K |
| Net cash provided by operating activities | $8.28M | $17.5M | $8.82M | -$-22.94M | -$-33.09M |
| Investments in property, plant and equipment | -$-1.87M | -$-1.49M | -$-200K | -$-370K | -$-250K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-1.01M | $0.00 |
| Net cash used for investing activities | $6.91M | -$-11.54M | -$-8.73M | -$-13.91M | -$-3.4M |
| Common stock issued | $9.19M | $0.00 | $16.2M | $0.00 | $14M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | -$-3.11M | -$-3.11M | -$-3.11M | -$-3.11M | -$-870K |
| Net cash used for financing activities | -$-13.41M | -$-4.12M | $29.1M | -$-530K | $68.6M |
| Net change in cash | $1.78M | $1.86M | $29.2M | -$-37.37M | $32.2M |
| Cash at end of period | $36.8M | $35M | $33.2M | $3.96M | $41.3M |
| Operating cash flow | $8.28M | $17.5M | $8.82M | -$-22.94M | -$-33.09M |
| Capital expenditure | -$-9.52M | -$-11.54M | -$-8.73M | -$-12.89M | -$-3.4M |
| Free cash flow | -$-1.24M | $5.98M | $90K | -$-35.83M | -$-36.49M |
Line items
Line items
Line items
About LifeMD, Inc.
LifeMD, Inc. operates as a leading digital health company, specializing in direct-to-consumer telemedicine across the United States. The firm links individuals with licensed medical professionals to address a diverse spectrum of health concerns, including concierge services, men's sexual health, dermatological conditions, and more. Under its umbrella, LifeMD manages several specialized virtual care platforms: ShapiroMD is a telehealth brand focused on hair restoration, delivering virtual consultations, prescription medications, patented over-the-counter formulations, an FDA-cleared medical device, and custom-compounded topical treatments for both male and female hair loss. RexMD serves as a men's telehealth brand, providing virtual medical treatment from licensed providers for a wide array of male-specific health needs. LifeMD Primary Care offers a personalized, subscription-based virtual primary care solution, addressing routine, urgent, and chronic health management requirements. This mobile-centric platform integrates remote consultations, medication management, diagnostic services, and imaging referrals. Cleared is a telehealth service dedicated to offering personalized therapies for allergic, asthmatic, and immunological conditions. Nava MD stands as a skincare and tele-dermatology brand catering specifically to women, facilitating virtual access to dermatologists and other specialists for medical treatment. Additionally, the company provides PDFSimpli, a cloud-based software-as-a-service (SaaS) platform that empowers users to create, edit, convert, sign, and share PDF documents online. LifeMD distributes its offerings directly to individuals, via its own e-commerce channels, and through collaborations with external partners. Originally established in 1994 as Conversion Labs, Inc., the company rebranded to LifeMD, Inc. in February 2021 and is headquartered in New York City.
- CEO
- Justin Schreiber
- Employees
- 389
- Beta
- 1.99
Explore
Frequently asked questions
What is the intrinsic value of LifeMD, Inc. (LFMD)?
InvestorsCraft does not currently publish an intrinsic value for LFMD. How the IC value is calculated.
Is LFMD undervalued?
InvestorsCraft does not publish an undervaluation signal for LFMD at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.